PriceTargets.com logo

BIOLASE - BIOL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $77.00
  • Forecasted Upside: 51,927.03%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.15 As of 04/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for BIOL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BIOLASE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOL

Analyst Price Target is $77.00
▲ +51,927.03% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for BIOLASE in the last 3 months. The average price target is $77.00, with a high forecast of $150.00 and a low forecast of $4.00. The average price target represents a 51,927.03% upside from the last price of $0.15.

This chart shows the closing price for BIOL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in BIOLASE. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2023BenchmarkLower Target$10.00 ➝ $4.00Low
5/31/2023Lake Street CapitalLower Target$150.00Low
3/29/2023BenchmarkReiterated RatingSpeculative Buy$200.00Low
1/20/2023Lake Street CapitalReiterated RatingBuyLow
11/16/2022Ascendiant Capital MarketsLower Target$1,400.00N/A
11/16/2022BenchmarkLower Target$700.00N/A
11/11/2022Maxim GroupLower Target$1,000.00 ➝ $500.00Low
5/20/2022Lake Street CapitalInitiated CoverageBuy$1,200.00High
3/22/2022Colliers SecuritiesReiterated RatingBuyLow
3/18/2022Maxim GroupInitiated CoverageBuy$3,750.00Medium
8/19/2021Ascendiant Capital MarketsBoost TargetPositive ➝ Buy$5,000.00 ➝ $7,500.00Low
5/14/2021Maxim GroupReiterated RatingBuy$5,000.00Low
3/26/2021Maxim GroupReiterated RatingBuy$5,000.00Low
3/8/2021Colliers SecuritiesReiterated RatingBuy$2,875.00High
1/26/2021Maxim GroupBoost TargetBuy$2,500.00 ➝ $5,000.00High
10/14/2020Maxim GroupInitiated CoverageBuy$2,500.00Low
8/12/2019Ascendiant Capital MarketsSet TargetBuy$7,500.00High
6/19/2019BenchmarkInitiated CoverageSpeculative Buy ➝ Speculative Buy$5,000.00High
4/30/2019Dougherty & CoReiterated RatingBuyHigh
(Data available from 4/28/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BIOLASE logo
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Read More

Today's Range

Now: $0.15
Low: $0.14
High: $0.15

50 Day Range

MA: $0.15
Low: $0.13
High: $0.19

52 Week Range

Now: $0.15
Low: $0.13
High: $32.09

Volume

688,002 shs

Average Volume

1,612,367 shs

Market Capitalization

$4.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of BIOLASE?

The following equities research analysts have issued stock ratings on BIOLASE in the last twelve months: Benchmark Co., Lake Street Capital, and StockNews.com.
View the latest analyst ratings for BIOL.

What is the current price target for BIOLASE?

2 Wall Street analysts have set twelve-month price targets for BIOLASE in the last year. Their average twelve-month price target is $77.00, suggesting a possible upside of 51,927.0%. Lake Street Capital has the highest price target set, predicting BIOL will reach $150.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $4.00 for BIOLASE in the next year.
View the latest price targets for BIOL.

What is the current consensus analyst rating for BIOLASE?

BIOLASE currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BIOL.

What other companies compete with BIOLASE?

Other companies that are similar to BIOLASE include Sonendo, Leafly, SunLink Health Systems, GT Biopharma and Oragenics. Learn More about companies similar to BIOLASE.

How do I contact BIOLASE's investor relations team?

BIOLASE's physical mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company's listed phone number is (949) 361-1200 and its investor relations email address is [email protected]. The official website for BIOLASE is www.biolase.com. Learn More about contacing BIOLASE investor relations.